| Line Item | 2025-10-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $93.2M | — | +16.1% |
| Cost of Revenue | $10.2M | — | +27.4% |
| R&D Expense | $20.9M | — | +22.6% |
| SG&A Expense | $15.4M | — | +109.2% |
| Pre-tax Income | $34.7M | — | +17.7% |
| Income Tax | $3.8M | — | +840.7% |
| Net Income | $30.9M | — | +2.8% |
| EPS (Basic) | $0.72 | — | -6.5% |
| EPS (Diluted) | $0.21 | — | -4.5% |
| Line Item | 2025-10-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $266.2M | — | +100.4% |
| Accounts Receivable | $32.1M | — | — |
| Current Assets | $742.8M | — | — |
| Total Assets | $810.6M | — | — |
| Current Liabilities | $440.8M | — | — |
| Total Liabilities | $458.1M | — | — |
| Line Item | 2025-10-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $118.9M | — | — |
| Investing Cash Flow | -$830K | — | — |
| Financing Cash Flow | $6.9M | — | — |
| Stockholders' Equity | $125.4M | +48.6% | +505.2% |